Item 8.01 Other Items.

On September 21, 2021, AbCellera Biologics Inc., (the "Company"), issued a press release announcing that the European Commission (EC) and Eli Lilly and Company (Lilly) have entered into a Joint Procurement Agreement to supply up to 220,000 doses of bamlanivimab together with etesivimab to treat confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19. A copy of the press release is attached herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits



(d) Exhibits


 Exhibit

   No.                                             Description
   99.1            Press Release issued by AbCellera Biologics Inc. on September 21, 2021  .
   104           Cover Page Interactive Data File (embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses